Irinotecan With Docetaxel in Treating Patients With Recurrent or Metastatic Non-small Cell Lung Cancer
Part of paid clinical trials in Scottsdale, Arizona.
- Sponsor
- Alliance for Clinical Trials in Oncology
- Study ID
- NCT00003900
- Phase
- PHASE2
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- docetaxel — DRUG
- irinotecan hydrochloride — DRUG
Study Details
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining irinotecan and docetaxel in treating patients who have recurrent or metastatic non-small cell lung cancer.
Key Dates
- Start date
- Oct 31, 1999
- Status verified
- Jul 2016
- Primary completion
- Mar 31, 2006
- Completion
- Mar 31, 2006
Study Design
- Enrollment
- 48 participants (actual)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: irinotecan + docetaxelPatients receive irinotecan IV over 90 minutes immediately followed by docetaxel IV over 60 minutes on day 1. Treatment is repeated every 3 weeks for 6 courses in the absence of disease progression or unacceptable toxicity. Patients are followed every 3 months for 5 years or until death.
Primary Outcome Measure
response rate [ Time Frame: Up to 5 years ]
Locations (18)
Find similar trials in Scottsdale, AZ
By condition
By specialty
By research site
CCOP - Scottsdale Oncology Program· Scottsdale, AZCCOP - Illinois Oncology Research Association· Peoria, ILCCOP - Carle Cancer Center· Urbana, ILCCOP - Cedar Rapids Oncology Project· Cedar Rapids, IACCOP - Iowa Oncology Research Association· Des Moines, IASiouxland Hematology-Oncology· Sioux City, IA
Related Studies
- A Phase 3 Study of 99mTC-EC-DG SPECT/CT Versus PET/CT in Lung CancerPHASE3 · Not Yet Recruiting · Cell>Point LLC · Decatur, Illinois
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or LymphomaPHASE1/PHASE2 · Recruiting · VM Oncology, LLC · Santa Rosa, California
- Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung CancerPHASE2/PHASE3 · Recruiting · Canadian Cancer Trials Group · Chicago, Illinois